An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Bern.”
The original article has been updated.
Summary
Keywords
purpura, thrombotic thrombocytopenic, ADAMTS13, mRNA SARS-CoV-2 vaccine, COVID-19 vaccine
Citation
Frontiers Production Office (2023) Erratum: Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: Case report and mini-review of the literature. Front. Med. 10:1186494. doi: 10.3389/fmed.2023.1186494
Received
14 March 2023
Accepted
14 March 2023
Published
27 March 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
10 - 2023
Updates
Copyright
© 2023 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office production.office@frontiersin.org
This article was submitted to Hematology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.